[Guillain-Barré syndrome].
Kusunoki
Susumu
S
Department of Neurology, Kinki University School of Medicine.
D000920:Antibody-Dependent Cell Cytotoxicity; D001323:Autoantibodies; D016123:Campylobacter jejuni / Q000276:immunology; D003167:Complement Activation; D005732:Gangliosides / Q000276:immunology; D006017:Glycolipids / Q000276:immunology; D020275:Guillain-Barre Syndrome / Q000175:diagnosis / Q000276:immunology / Q000503:physiopathology / Q000628:therapy; D006801:Humans; D007111:Immunity, Cellular; D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage; D010956:Plasmapheresis; D011379:Prognosis; D013601:T-Lymphocytes / Q000276:immunology
D001323:Autoantibodies; D005732:Gangliosides; D006017:Glycolipids; D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous; C039129:GQ1b ganglioside